AGA临床实践更新:肝硬化患者门静脉血栓管理专家综述
美国胃肠病学协会(AGA)发布专家综述,为肝硬化门静脉血栓(PVT)的评估与管理提供最佳实践建议,涵盖筛查、影像确认、抗凝指征、药物选择及血管内干预。建议基于文献回顾与专家意见,未进行系统评价,因此不携带正式的证据质量或推荐强度评级。
要点
- 多普勒超声发现PVT后应行CT或MRI确认诊断、排查恶性肿瘤并记录管腔闭塞程度、血栓范围和慢性程度。
- 无肠缺血且近期(<6个月)血栓累及肝内门静脉分支或主干/脾静脉/肠系膜静脉闭塞<50%者可考虑观察,每3个月复查影像。
- 无肠缺血但近期(<6个月)PVT闭塞>50%或累及门静脉主干或肠系膜血管者应考虑抗凝。
核心结论
- 对肝硬化PVT患者应根据血栓范围、闭塞程度、慢性程度及肠缺血情况个体化选择观察或抗凝,维生素K拮抗剂、低分子肝素和直接口服抗凝药均为合理选择,经颈静脉肝内门体分流术可用于特定患者。
研究设计与样本
- AGA研究所临床实践更新委员会委托并批准的专家综述,经内部同行评议和《Gastroenterology》标准外部同行评议,建议来自已发表文献回顾和专家意见,未进行系统评价。
诊断标准与关键数值
- 代偿期肝硬化无症状患者不需要常规筛查PVT。
- 多普勒超声发现PVT后应行CT或MRI确认诊断、评估恶性肿瘤并记录管腔闭塞程度、血栓范围和慢性程度。
- 无额外血栓栓塞、实验室异常或提示易栓症家族史者不需要高凝状态检查。
- 有肠缺血证据的PVT患者需紧急抗凝以尽量减少缺血损伤,并应由包括胃肠病和肝病科、介入放射科、血液科和外科的多学科团队管理。
- 无肠缺血且近期(<6个月)血栓累及肝内门静脉分支或门静脉主干、脾静脉或肠系膜静脉闭塞<50%者,可考虑观察并每3个月复查影像直至血栓消退。
临床应用与阅片要点
- 多普勒超声发现PVT后应行CT或MRI确认诊断、评估恶性肿瘤并记录管腔闭塞程度、血栓范围和慢性程度。
- 根据血栓范围(肝内分支 vs 主干/脾静脉/肠系膜静脉)、闭塞程度(<50% vs >50%)、慢性程度(<6个月 vs >6个月)和有无肠缺血选择观察或抗凝。
- 抗凝治疗中每3个月行横断面影像评估治疗反应。
- 避免延迟启动抗凝,因延迟会降低门静脉再通几率。
局限性
- 未进行系统评价,最佳实践建议不携带关于证据质量或推荐强度的正式评级。
- 建议来自已发表文献回顾和专家意见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
DESCRIPTION: Portal vein thromboses (PVTs) are common in patients with cirrhosis and are associated with advanced portal hypertension and mortality. The treatment of PVTs remains a clinical challenge due to limited evidence and competing risks of PVT-associated complications vs bleeding risk of anticoagulation. Significant heterogeneity in PVT phenotype based on anatomic, host, and disease characteristics, and an emerging spectrum of therapeutic options further complicate PVT management. This Clinical Practice Update (CPU) aims to provide best practice advice for the evaluation and management of PVT in cirrhosis, including the role of direct oral anticoagulants and endovascular interventions.
METHODS: This expert review was commissioned and approved by the American Gastroenterological Association (AGA) Institute CPU Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the CPU Committee and external peer review through standard procedures of Gastroenterology. These Best Practice Advice statements were drawn from a review of the published literature and from expert opinion. Because systematic reviews were not performed, these Best Practice Advice statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. Best Practice Advice Statements BEST PRACTICE ADVICE 1: Asymptomatic patients with compensated cirrhosis do not require routine screening for PVT. BEST PRACTICE ADVICE 2: Patients with cirrhosis with PVTs identified on Doppler ultrasound should undergo cross-sectional imaging with computed tomography or magnetic resonance imaging to confirm the diagnosis, evaluate for malignancy, and document the degree of lumen occlusion, clot extent, and chronicity. BEST PRACTICE ADVICE 3: Patients with cirrhosis and PVT do not require a hypercoagulable workup in the absence of additional thromboemboli or laboratory abnormalities or family history suggestive of thrombophilia. BEST PRACTICE ADVICE 4: Patients with cirrhosis and PVT with evidence of intestinal ischemia require urgent anticoagulation to minimize ischemic injury. If available, these patients should be managed by a multidisciplinary team, including gastroenterology and hepatology, interventional radiology, hematology, and surgery. BEST PRACTICE ADVICE 5: Consider observation, with repeat imaging every 3 months until clot regression, in patients with cirrhosis without intestinal ischemia and recent (<6 months) thrombosis involving the intrahepatic portal vein branches or when there is <50% occlusion of the main portal vein, splenic vein, or mesenteric veins. BEST PRACTICE ADVICE 6: Anticoagulation should be considered in patients with cirrhosis without intestinal ischemia who develop recent (<6 months) PVT that is >50% occlusive or involves the main portal vein or mesenteric vessels. Patients who have increased benefit of recanalization include those with involvement of more than 1 vascular bed, those with thrombus progression, potential liver transplantation candidates, and those with inherited thrombophilia. BEST PRACTICE ADVICE 7: Anticoagulation is not advised for patients with cirrhosis with chronic (>6 months) PVT with complete occlusion with collateralization (cavernous transformation). BEST PRACTICE ADVICE 8: Patients with cirrhosis and PVT warrant endoscopic variceal screening if they are not already on nonselective beta-blocker therapy for bleeding prophylaxis. Avoid delays in the initiation of anticoagulation for PVT, as this decreases the odds of portal vein recanalization. BEST PRACTICE ADVICE 9: Vitamin K antagonists, low-molecular-weight heparin, and direct oral anticoagulants are all reasonable anticoagulant options for patients with cirrhosis and PVT. Decision making should be individualized and informed by patient preference and Child-Turcotte-Pugh class. Direct oral anticoagulants may be considered in patients with compensated Child-Turcotte-Pugh class A and Child-Turcotte-Pugh class B cirrhosis and offer convenience as their dosages are independent of international normalized ratio monitoring. BEST PRACTICE ADVICE 10: Patients with cirrhosis on anticoagulation for PVT should have cross-sectional imaging every 3 months to assess response to treatment. If clot regresses, anticoagulation should be continued until transplantation or at least clot resolution in nontransplantation patients. BEST PRACTICE ADVICE 11: Portal vein revascularization with transjugular intrahepatic portosystemic shunting may be considered for selected patients with cirrhosis and PVT who have additional indications for transjugular intrahepatic portosystemic shunting, such as those with refractory ascites or variceal bleeding. Portal vein revascularization with transjugular intrahepatic portosystemic shunting may also be considered for transplantation candidates if recanalization can facilitate the technical feasibility of transplantation.
引用
- Davis JPE, Lim JK, Francis FF, et al. AGA Clinical Practice Update on Management of Portal Vein Thrombosis in Patients With Cirrhosis: Expert Review. Gastroenterology. 2024. PMID: 39708000. doi:10.1053/j.gastro.2024.10.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。